Biomarker-based corticosteroid adjustment in severe asthma: a modified Delphi consensus by Gallagher, Nicola E. et al.
Biomarker-based corticosteroid
adjustment in severe asthma:
a modified Delphi consensus
To the Editor:
Asthma is managed using “step-wise” adjustment of corticosteroid therapy to achieve asthma control.
When corticosteroid treatment is adjusted using sputum eosinophil count or exhaled nitric oxide fraction,
exacerbations are reduced [1, 2]; however, implementation in clinical care has been slow. In parallel,
airway transcriptomic analysis has demonstrated that type 2 eosinophilic inflammation is absent in many
patients with minimal response to corticosteroid treatment [3–5]. The UK Refractory Asthma Stratification
Programme (RASP-UK) (http://rasp.org.uk/) is exploring non-sputum biomarker-based strategies to target
corticosteroid treatment in severe asthma [6, 7], and sought to determine clinician and patient views on
clinically relevant reductions in corticosteroid treatment.
Three expert physician groups in severe asthma management participated in an online anonymous
modified Delphi process [8] (three rounds): 1) RASP-UK Investigators (n=21), 2) UK severe asthma
physicians not in RASP-UK (n=16) and 3) the European Respiratory Society Severe Asthma Clinical
Research Collaboration [9] (n=22). 41 out of 59 physicians completed the process to achieve final
statement consensus (>75% agreement) (figure 1). An identical process using a patient-focused
questionnaire was sent to severe asthma patients from Asthma UK’s Expert Patient Group (two rounds
achieved consensus; 16 out of 23 completed the first round and 12 completed the second round).
A RASP-UK investigator and statistician composed the questions. After the first round, the questions of
subsequent rounds were adapted based on the responses from the previous round.
The final consensus statements and levels of agreement were as follows.
Statement 1
Do you believe that biomarker-based adjustment of corticosteroid dose is currently the optimal way to adjust




Only 39% of the European group (group 3) agreed, compared to 68% of the RASP-UK (group 1) and 67%
of the UK non-RASP (group 2) physicians. Currently, 44% of European physicians use biomarker-based
corticosteroid adjustment routinely compared with 95% (group 1) and 100% (group 2).
Patient view
No consensus was reached on patient preference on corticosteroid adjustment using symptoms or
biomarkers (50% each). The majority (75%) believed their corticosteroid was currently adjusted using
symptoms/lung function.
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Statement 2
Accepting that nonadherence may be both intentional and unintentional, do you agree that between 30% and
50% of severe asthma patients in the most severe and difficult asthma clinics are poorly adherent with inhaled
corticosteroid treatment as the primary clinical problem?
Consensus achieved
Physician view
Group 1 felt this proportion was 30–50%, group 2 thought 25–50% and group 3 thought 20–50%.
Patient view
94% of patients reported they would never miss taking their inhalers.
Statement 3a
Do you agree that at least 5 mg (or 2.5 mg if on ⩽10 mg·day−1) reduction in daily oral prednisolone would be
regarded as a clinically meaningful reduction?
Consensus achieved
Uncertainty as to clinicians' opinions of using a biomarker-based
  management approach to corticosteroid adjustment versus
  symptoms, lung function and exacerbation history
What level of steroid reduction is required to define using a
  biomarker-based algorithm as clinically worthwhile?
Definition of problem
Respiratory physicians specialising in the management of patients
with difficult asthma:
  59 specialist physicians selected with experience in treating severe
  asthma
    Group 1: RASP-UK PIs
    Group 2: UK severe asthma physicians not involved in RASP-UK
    Group 3: Members and collaborators with the European Severe
      Asthma Clinical Research Collaboration SHARP
Selection of expert panel
Questionnaire posted online with 10 questionsFirst round of Delphi
Results analysed for degree of consensus
Results from first round summarised and participants agree or
  disagree with majority result
Participants could comment if necessary
Responses analysed for level of consensus
Second round of Delphi
Results from second round summarised and participants agree or
  disagree with statements
Third round of Delphi
FIGURE 1 Modified Delphi process used to reach a consensus among experts in severe asthma regarding the
degree of benefit of biomarker-based adjustment of corticosteroid treatment required to make the conversion
to a biomarker algorithm from current standard care worthwhile. RASP-UK: UK Refractory Asthma
Stratification Programme; PI: principal investigator; SHARP: Severe Heterogeneous Asthma Research
collaboration, Patient-centred.
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Statement 3b
If you treat patients with asthma on maintenance oral steroids, do you agree that at least 25% of patients would
be required to be on this optimised “lower” dose of daily oral prednisolone treatment to justify routine use of
biomarker-based corticosteroid treatment adjustment in routine clinical care?
Consensus achieved
Physician view
All expert physician groups agreed that at least 5 mg (or 2.5 mg if ⩽10 mg·day−1) reduction in
prednisolone was clinically meaningful. Group 1 thought that at least 25% of patients would need to make
this reduction to justify a biomarker-based strategy, whilst groups 2 and 3 thought at least 20%.
Patient view
91% of patients felt any reduction in oral corticosteroids would make blood/breath tests worthwhile.
Statement 4a
Do you agree that in a severe asthma population on high-dose inhaled steroids (2000 µg beclomethasone
dipropionate equivalent dose) that at least a 500 µg reduction in daily inhaled corticosteroid treatment would be
regarded as a clinically meaningful dose reduction?
Consensus not achieved
Statement 4b
Do you agree that at least 30% of patients would be required to be on this optimised “lower” dose of daily




Group 1 agreed that at least 500 µg reduction was clinically meaningful and group 2 thought this was at
least 250 µg reduction. For group 3, 62% felt that at least 250 µg reduction was clinically meaningful
(no consensus). Groups 1 and 2 agreed that at least 30% of patients would need to be on this optimised
lower dose to justify using a biomarker-based adjustment strategy; for group 3, 54% felt that at least 40%
of patients would need to achieve this (no consensus).
Patient view
73% of patients felt that additional blood/breath tests would be worthwhile if they led to any reduction in
inhaled corticosteroid treatment.
Statement 5
Accepting at least three exacerbations per year (requiring oral corticosteroid rescue therapy), do you agree that at




Group 1 agreed that at least a 30% reduction in asthma exacerbations per year would justify routine use of
biomarker-based corticosteroid treatment adjustment whereas groups 2 and 3 agreed that at least a 20%
reduction would justify routine use.
Patient view
44% of patients had three or more asthma attacks in the previous year requiring oral corticosteroids.
All patients thought that having regular blood and breath tests would be worthwhile if this prevented
one attack.
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Statement 6
Excluding patients where persistent symptoms of cough, wheeze and breathlessness are due to comorbid
conditions (e.g. obesity, vocal cord dysfunction, dysfunctional breathing, rhinosinusitis, etc.), do you agree that at




Groups 1 and 2 agreed at least 25% and group 3 agreed at least 20% of severe asthma patients have
persistent symptoms due to asthma that are not corticosteroid responsive.
Patient view
91% of patients agreed that not all their symptoms responded to inhaled or oral steroids.
The RASP-UK programme is exploring if a non-sputum biomarker-based adjustment of corticosteroid
treatment is clinically more beneficial than standard care [7]. In this modified Delphi exercise, consensus
was reached on all issues for groups 1 and 2. However, for group 3, consensus was not reached on a
number of issues, including clinically meaningful dose reduction in inhaled corticosteroid treatment and
proportion of patients reducing inhaled corticosteroid treatment to justify routine use of biomarkers.
Overall, European experts appeared less supportive of biomarker-based corticosteroid adjustment
compared to UK physicians and correctly stated that although sputum eosinophil count was evidence
based, delivery was difficult in routine care and the optimal combination of non-sputum-based biomarkers
was unknown [10, 11].
Patient views are critical in understanding acceptance of treatment strategies and there was no consensus
on corticosteroid treatment adjustment using symptoms versus biomarkers, suggesting education may be
required on the utility of biomarkers in targeting treatment. The majority felt any reduction in inhaled/
oral corticosteroid dose or eradicating one severe exacerbation would make biomarker tests worthwhile.
Patients felt regular blood and breath tests were unlikely to improve adherence; however, this small
motivated group reported never missing medication. The group of patients who took part in this survey
volunteered for Asthma UK and some were also involved in the Patient Input Platform for the RASP-UK
programme. These patients may, therefore, have had greater knowledge regarding severe asthma and
biomarkers.
In conclusion, we present a consensus view of severe asthma expert physicians on non-sputum
biomarker-based corticosteroid adjustment and the scale of benefit that would persuade them to use
biomarkers in routine clinical care. A small number of nonconsensual issues were identified, where
European group experts appeared to be less supportive of biomarker-based adjustment of asthma
treatment compared to UK physicians.
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